{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:37:12Z","timestamp":1792805832400,"version":"4.5.0"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,1,17]],"date-time":"2020-01-17T00:00:00Z","timestamp":1579219200000},"content-version":"vor","delay-in-days":16,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1007\/s40263-019-00689-1","type":"journal-article","created":{"date-parts":[[2020,1,17]],"date-time":"2020-01-17T11:02:52Z","timestamp":1579258972000},"page":"9-27","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":109,"title":["Recently Approved and Upcoming Treatments for Narcolepsy"],"prefix":"10.1007","volume":"34","author":[{"given":"Michael J.","family":"Thorpy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,17]]},"reference":[{"key":"689_CR1","doi-asserted-by":"crossref","first-page":"16100","DOI":"10.1038\/nrdp.2016.100","volume":"3","author":"BR Kornum","year":"2017","unstructured":"Kornum BR, Knudsen S, Ollila HM, Pizza F, Jennum PJ, Dauvilliers Y, et al. Narcolepsy. Nat Rev Dis Prim. 2017;3:16100.","journal-title":"Nat Rev Dis Prim."},{"key":"689_CR2","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.smrv.2018.09.006","volume":"43","author":"ST Szabo","year":"2019","unstructured":"Szabo ST, Thorpy MJ, Mayer G, Peever JH, Kilduff TS. Neurobiological and immunogenetic aspects of narcolepsy: implications for pharmacotherapy. Sleep Med Rev. 2019;43:23\u201336.","journal-title":"Sleep Med Rev."},{"key":"689_CR3","first-page":"125","volume-title":"Narcolepsy and hypersomnia","author":"MM Ohayon","year":"2007","unstructured":"Ohayon MM. Epidemiology of narcolepsy. In: Bassetti C, Mignot E, Billard M, editors. Narcolepsy and hypersomnia. New York: Taylor and Francis; 2007. p. 125\u201332."},{"issue":"2","key":"689_CR4","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1093\/sleep\/25.2.197","volume":"25","author":"MH Silber","year":"2002","unstructured":"Silber MH, Krahn LE, Olson EJ, Pankratz VS. The epidemiology of narcolepsy in Olmsted County, Minnesota: a population-based study. Sleep. 2002;25(2):197\u2013202.","journal-title":"Sleep."},{"issue":"5","key":"689_CR5","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.sleep.2014.01.015","volume":"15","author":"MJ Thorpy","year":"2014","unstructured":"Thorpy MJ, Krieger AC. Delayed diagnosis of narcolepsy: characterization and impact. Sleep Med. 2014;15(5):502\u20137.","journal-title":"Sleep Med."},{"issue":"7","key":"689_CR6","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/nrneurol.2014.97","volume":"10","author":"Y Dauvilliers","year":"2014","unstructured":"Dauvilliers Y, Siegel JM, Lopez R, Torontali ZA, Peever JH. Cataplexy\u2013clinical aspects, pathophysiology and management strategy. Nat Rev Neurol. 2014;10(7):386\u201395.","journal-title":"Nat Rev Neurol."},{"key":"689_CR7","volume-title":"International classification of sleep disorders","author":"American Academy of Sleep Medicine","year":"2014","unstructured":"American Academy of Sleep Medicine. International classification of sleep disorders. 3rd ed. Darien: American Academy of Sleep Medicine; 2014.","edition":"3"},{"key":"689_CR8","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2147\/NSS.S103467","volume":"9","author":"VC Abad","year":"2017","unstructured":"Abad VC, Guilleminault C. New developments in the management of narcolepsy. Nat Sci Sleep. 2017;9:39\u201357.","journal-title":"Nat Sci Sleep."},{"issue":"11","key":"689_CR9","first-page":"1","volume":"42","author":"Y Dauvilliers","year":"2019","unstructured":"Dauvilliers Y, Arnulf I, Szakacs Z, Leu-Semenescu S, Lecomte I, Scart-Gres C, et al. Long-term use of pitolisant to treat patients with narcolepsy: Harmony\u00a0III study. Sleep Biol Rhythms. 2019;42(11):1\u201311.","journal-title":"Sleep Biol Rhythms."},{"issue":"4","key":"689_CR10","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1111\/j.1476-5381.2011.01286.x","volume":"163","author":"JC Schwartz","year":"2011","unstructured":"Schwartz JC. The histamine H3 receptor: from discovery to clinical trials with pitolisant. Br J Pharmacol. 2011;163(4):713\u201321.","journal-title":"Br J Pharmacol."},{"key":"689_CR11","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.2147\/DDDT.S101145","volume":"12","author":"A Romigi","year":"2018","unstructured":"Romigi A, Vitrani G, Lo Giudice T, Centonze D, Franco V. Profile of pitolisant in the management of narcolepsy: design, development, and place in therapy. Drug Des Dev Ther. 2018;12:2665\u201375.","journal-title":"Drug Des Dev Ther."},{"key":"689_CR12","unstructured":"Wakix [summary of product characteristics]. Paris: Bioprojet Pharm; 2019."},{"key":"689_CR13","unstructured":"Wakix [package insert]. Plymouth Meeting: Harmony Biosciences; 2019."},{"key":"689_CR14","unstructured":"Harmony Biosciences announces file acceptance of its new drug application for pitolisant [press release]. 2019. https:\/\/www.harmonybiosciences.com\/newsroom\/harmony-biosciences-announces-file-acceptance-of-its-new-drug-application\/. Accessed 02 May 2019."},{"issue":"1","key":"689_CR15","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1124\/jpet.106.111039","volume":"320","author":"X Ligneau","year":"2007","unstructured":"Ligneau X, Perrin D, Landais L, Camelin JC, Calmels TP, Berrebi-Bertrand I, et al. BF2.649 [1-{3-[3-(4-chlorophenyl)propoxy]propyl}piperidine, hydrochloride], a nonimidazole inverse agonist\/antagonist at the human histamine H3 receptor: preclinical pharmacology. J Pharmacol Exp Ther. 2007;320(1):365\u201375.","journal-title":"J Pharmacol Exp Ther"},{"key":"689_CR16","unstructured":"EMA. Wakix assessment report. 2015. https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/wakix-epar-public-assessment-report_en.pdf. Accessed 29 Apr 2019"},{"key":"689_CR17","doi-asserted-by":"crossref","unstructured":"Robert P, Schwartz JC. Hormonal contraceptive and pitolisant CYP3A4 induction [abstract]. Neurology. 2019;92(15 suppl):P3.6-035.","DOI":"10.1212\/WNL.92.15_supplement.P3.6-035"},{"issue":"Supplement_1","key":"689_CR18","doi-asserted-by":"crossref","first-page":"A245","DOI":"10.1093\/sleep\/zsz067.613","volume":"42","author":"Karl Doghramji","year":"2019","unstructured":"Doghramji K, Davis CW, Patroneva A, Schwartz JC, Scart-Gres C, Robert P, et al. Pitolisant in combination with other medications for the management of narcolepsy [abstract no. 0615]. Sleep. 2019;42(suppl 1):A245.","journal-title":"Sleep"},{"issue":"11","key":"689_CR19","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/S1474-4422(13)70225-4","volume":"12","author":"Y Dauvilliers","year":"2013","unstructured":"Dauvilliers Y, Bassetti C, Lammers GJ, Arnulf I, Mayer G, Rodenbeck A, et al. Pitolisant versus placebo or modafinil in patients with narcolepsy: a double-blind, randomised trial. Lancet Neurol. 2013;12(11):1068\u201375.","journal-title":"Lancet Neurol."},{"issue":"3","key":"689_CR20","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S1474-4422(16)30333-7","volume":"16","author":"Z Szakacs","year":"2017","unstructured":"Szakacs Z, Dauvilliers Y, Mikhaylov V, Poverennova I, Krylov S, Jankovic S, et al. Safety and efficacy of pitolisant on cataplexy in patients with narcolepsy: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017;16(3):200\u20137.","journal-title":"Lancet Neurol."},{"issue":"suppl 1","key":"689_CR21","doi-asserted-by":"crossref","first-page":"A244","DOI":"10.1093\/sleep\/zsz067.612","volume":"42","author":"C Scart-Gres","year":"2019","unstructured":"Scart-Gres C, Momah C, Roy M, Maski K, Piris S, Bogan RK. Safety and tolerability of pitolisant in the treatment of adults with narcolepsy: integrated data from clinical studies [abstract no. 0614]. Sleep. 2019;42(suppl 1):A244\u20135.","journal-title":"Sleep."},{"issue":"Supplement_1","key":"689_CR22","doi-asserted-by":"crossref","first-page":"A243","DOI":"10.1093\/sleep\/zsz067.609","volume":"42","author":"Eric D Bauer","year":"2019","unstructured":"Bauer ED, Davis CW, Patroneva A, Dayno JM, Thorpy MJ. The safety and tolerability of pitolisant in the treatment of excessive daytime sleepiness and cataplexy in adult patients with narcolepsy: an open-label, expanded access program in the United States [abstract no. 0611]. Sleep. 2019;42(suppl 1):A243.","journal-title":"Sleep"},{"issue":"Supplement_1","key":"689_CR23","doi-asserted-by":"crossref","first-page":"A244","DOI":"10.1093\/sleep\/zsz067.611","volume":"42","author":"Ulf Kallweit","year":"2019","unstructured":"Kallweit U, Triller A. Effects of pitolisant on nighttime sleep [abstract no. 0613]. Sleep. 2019;42(suppl 1):A244.","journal-title":"Sleep"},{"issue":"3","key":"689_CR24","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/bph.12149","volume":"169","author":"M Uguen","year":"2013","unstructured":"Uguen M, Perrin D, Belliard S, Ligneau X, Beardsley PM, Lecomte JM, et al. Preclinical evaluation of the abuse potential of pitolisant, a histamine H(3) receptor inverse agonist\/antagonist compared with modafinil. Br J Pharmacol. 2013;169(3):632\u201344.","journal-title":"Br J Pharmacol."},{"key":"689_CR25","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsz252","author":"B Setnik","year":"2019","unstructured":"Setnik B, McDonnell M, Mills C, Scart-Gres C, Robert P, Dayno JM, et al. Evaluation of the abuse potential of pitolisant, a selective H3-receptor antagonist\/inverse agonist, for the treatment of adult patients with narcolepsy with or without cataplexy. Sleep. 2019. https:\/\/doi.org\/10.1093\/sleep\/zsz252.","journal-title":"Sleep"},{"key":"689_CR26","unstructured":"Sunosi\u00ae (solriamfetol) tablets [prescribing information]. Palo Alto: Jazz Pharmaceuticals, Inc.; 2019."},{"issue":"2","key":"689_CR27","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1124\/jpet.118.248120","volume":"366","author":"MG Baladi","year":"2018","unstructured":"Baladi MG, Forster MJ, Gatch MB, Mailman RB, Hyman DL, Carter LP, et al. Characterization of the neurochemical and behavioral effects of solriamfetol (JZP-110), a selective dopamine and norepinephrine reuptake inhibitor. J Pharmacol Exp Ther. 2018;366(2):367\u201376.","journal-title":"J Pharmacol Exp Ther."},{"issue":"2","key":"689_CR28","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.clinthera.2018.12.001","volume":"41","author":"K Zomorodi","year":"2019","unstructured":"Zomorodi K, Kankam M, Lu Y. A phase I, randomized, crossover, open-label study of the pharmacokinetics of solriamfetol (JZP-110) in healthy adult subjects with and without food. Clin Ther. 2019;41(2):196\u2013204.","journal-title":"Clin Ther."},{"issue":"8","key":"689_CR29","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1002\/jcph.1402","volume":"59","author":"K Zomorodi","year":"2019","unstructured":"Zomorodi K, Chen D, Lee L, Lasseter K, Marbury T. Single-dose pharmacokinetics and safety of solriamfetol in participants with normal or impaired renal function and with end-stage renal disease requiring hemodialysis. J Clin Pharmacol. 2019;59(8):1120\u20139.","journal-title":"J Clin Pharmacol."},{"issue":"7","key":"689_CR30","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.5665\/sleep.5968","volume":"39","author":"C Ruoff","year":"2016","unstructured":"Ruoff C, Swick TJ, Doekel R, Emsellem HA, Feldman NT, Rosenberg R, et al. Effect of oral JZP-110 (ADX-N05) on wakefulness and sleepiness in adults with narcolepsy: a phase 2b study. Sleep. 2016;39(7):1379\u201387.","journal-title":"Sleep."},{"issue":"3","key":"689_CR31","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/ana.25423","volume":"85","author":"MJ Thorpy","year":"2019","unstructured":"Thorpy MJ, Shapiro C, Mayer G, Corser BC, Emsellem H, Plazzi G, et al. A randomized study of solriamfetol for excessive sleepiness in narcolepsy. Ann Neurol. 2019;85(3):359\u201370.","journal-title":"Ann Neurol."},{"key":"689_CR32","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsz220","author":"A Malhotra","year":"2019","unstructured":"Malhotra A, Shapiro C, Pepin JL, Hedner J, Ahmed M, Foldvary-Schaefer N, et al. Long-term study of the safety and maintenance of efficacy of solriamfetol (JZP-110) in the treatment of excessive sleepiness in participants with narcolepsy or obstructive sleep apnea. Sleep. 2019. https:\/\/doi.org\/10.1093\/sleep\/zsz220.","journal-title":"Sleep"},{"key":"689_CR33","unstructured":"Zomorodi K, Chen D, Lee L, Swearingen D. A randomized, double-blind, placebo- and positive-controlled, four-period crossover study of the effects of solriamfetol (JZP-110) on QTcF intervals in healthy participants [poster]. Annual Meeting of the American College of Clinical Pharmacology; 23\u201325 Sep 2018; Bethesda."},{"issue":"12","key":"689_CR34","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1177\/0269881118796814","volume":"32","author":"LP Carter","year":"2018","unstructured":"Carter LP, Henningfield JE, Wang YG, Lu Y, Kelsh D, Vince B, et al. A randomized, double-blind, placebo-controlled, crossover study to evaluate the human abuse liability of solriamfetol, a selective dopamine and norepinephrine reuptake inhibitor. J Psychopharmacol. 2018;32(12):1351\u201361.","journal-title":"J Psychopharmacol."},{"key":"689_CR35","unstructured":"Provigil [package insert]. North Wales: Teva Pharmaceuticals; 2018."},{"key":"689_CR36","unstructured":"Bron M, Franek J, Ronnebaum S, Menno D, Bujanover S, Stepnowsky C. Indirect treatment comparison of the efficacy of solriamfetol (JZP-110), modafinil, and armodafinil for the treatment of excessive sleepiness in obstructive sleep apnea [poster]. Annual Meeting of the Academy of Managed Care Pharmacy Nexus; 22\u201325 Oct 2018; Orlando."},{"key":"689_CR37","unstructured":"Avadel Pharmaceuticals receives orphan drug designation from FDA for FT 218 for the treatment of narcolepsy [press release]. 2018. http:\/\/investors.avadel.com\/news-releases\/news-release-details\/avadel-pharmaceuticals-receives-orphan-drug-designation-fda-ft?ID=2325927&c=67519&p=irol-newsArticle. Accessed 26 Apr 2019."},{"key":"689_CR38","unstructured":"Sodium oxybate controlled release\u2014Avadel Pharmaceuticals [drug profile]. Adis Insight; 2018. https:\/\/adisinsight.springer.com\/drugs\/800041142. Accessed 27 Nov 2019."},{"key":"689_CR39","unstructured":"Xyrem\u00ae (sodium oxybate) oral solution [prescribing information]. Palo Alto: Jazz Pharmaceuticals; 2018."},{"issue":"Supplement_1","key":"689_CR40","doi-asserted-by":"crossref","first-page":"A242","DOI":"10.1093\/sleep\/zsz067.607","volume":"42","author":"David Monteith","year":"2019","unstructured":"Monteith D, Grassot J, Castellan C, Roth T. Pharmacokinetics and formulation selection of Ft218, an investigational controlled-release sodium oxybate formulation designed for once nightly dosing [abstract no. 0609]. Sleep. 2019;42(suppl 1):A242\u20133.","journal-title":"Sleep"},{"issue":"Supplement_1","key":"689_CR41","doi-asserted-by":"crossref","first-page":"A243","DOI":"10.1093\/sleep\/zsz067.608","volume":"42","author":"David Monteith","year":"2019","unstructured":"Monteith D, Grassot J, Castellan C, Roth T. Pharmacokinetics and dose proportionality of FT218, an investigational controlled release formulation of sodium oxybate for once nightly dosing [abstract no. 0610]. Sleep. 2019;42(suppl 1):A243.","journal-title":"Sleep"},{"key":"689_CR42","unstructured":"A study to compare the absorption into the body of the drug sodium oxybate in FT218 in comparison to the currently marketed product Xyrem\u00ae\u00a0[EudraCT2016-004342-28]. 2017 Oct 17. https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2016-004342-28\/NL. Accessed 29 Apr 2019."},{"key":"689_CR43","unstructured":"Sodium oxybate for treatment of excessive daytime sleepiness and cataplexy in narcolepsy [ClinicalTrials.gov identifier NCT02720744]. National Institutes of Health, ClinicalTrials.gov. 2019.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02720744. Accessed 29 Apr 2019."},{"key":"689_CR44","unstructured":"Jazz Pharmaceuticals announces positive top-line results from phase 3 study of JZP-258 in adult narcolepsy patients with cataplexy and excessive daytime sleepiness [press release]. 2019. https:\/\/investor.jazzpharma.com\/news-releases\/news-release-details\/jazz-pharmaceuticals-announces-positive-top-line-results-phase-3. Accessed 26 Apr 2019."},{"key":"689_CR45","unstructured":"JZP 258 [drug profile]: Adis Insight; 2019. https:\/\/adisinsight.springer.com\/drugs\/800048256. Accessed 27 Nov 2019."},{"key":"689_CR46","doi-asserted-by":"crossref","unstructured":"Chen C, Skowronski R, Jenkins J, Zomorodi K. Pharmacokinetics, relative bioavailability, and food effect of JZP-258 and sodium oxybate: results of two phase 1, open-label, randomised crossover studies in healthy volunteers [abstract]. Biennial World Sleep Congress; 20\u201325 Sep 2019; Vancouver.","DOI":"10.1016\/j.sleep.2019.11.179"},{"key":"689_CR47","doi-asserted-by":"crossref","unstructured":"Bogan R, Thorpy M, Dauvilliers Y, Del Rio Villegas R, Foldvary-Schaefer N, Skowronski R, et al. Efficacy and safety of JZP-258 in a phase 3 double-blind, placebo-controlled, randomised-withdrawl study in adults with narcolepsy with cataplexy [abstract]. Biennial World Sleep Congress; 20\u201325 Sep 2019; Vancouver.","DOI":"10.1016\/j.sleep.2019.11.120"},{"key":"689_CR48","doi-asserted-by":"crossref","unstructured":"Dauvilliers Y, Sonka K, Bogan RK, Partinen M, Del Rio Villegas R, Foldvary-Schaefer N, et al. Changes in cataplexy frequency by prior therapy in a phase 3, double-blind, placebo-controlled, randomised withdrawal study of JZP-258 in adults with narcolepsy with cataplexy [abstract]. Biennial World Sleep Congress; 20\u201325 Sep 2019; Vancouver.","DOI":"10.1016\/j.sleep.2019.11.235"},{"key":"689_CR49","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.sleep.2017.03.028","volume":"35","author":"P Drakatos","year":"2017","unstructured":"Drakatos P, Lykouras D, D\u2019Ancona G, Higgins S, Gildeh N, Macavei R, et al. Safety and efficacy of long-term use of sodium oxybate for narcolepsy with cataplexy in routine clinical practice. Sleep Med. 2017;35:80\u20134.","journal-title":"Sleep Med."},{"key":"689_CR50","unstructured":"Axsome announces AXS-12 for narcolepsy [press release]. 2018. https:\/\/axsometherapeuticsinc.gcs-web.com\/static-files\/fa862bca-7be0-4849-9f00-68894655ab86. Accessed 26 Apr 2019."},{"key":"689_CR51","unstructured":"Axsome Therapeutics receives FDA orphan drug designation for AXS-12 for the treatment of narcolepsy [press release]. 2018. https:\/\/axsometherapeuticsinc.gcs-web.com\/news-releases\/news-release-details\/axsome-therapeutics-receives-fda-orphan-drug-designation-axs-12?field_nir_news_date_value%5bmin%5d=2019. Accessed 26 Apr 2019."},{"key":"689_CR52","unstructured":"Edronax [summary of product characteristics]. Kent: Pfizer Limited; 2015."},{"key":"689_CR53","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.bbr.2016.04.033","volume":"308","author":"C Schmidt","year":"2016","unstructured":"Schmidt C, Leibiger J, Fendt M. The norepinephrine reuptake inhibitor reboxetine is more potent in treating murine narcoleptic episodes than the serotonin reuptake inhibitor escitalopram. Behav Brain Res. 2016;308:205\u201310.","journal-title":"Behav Brain Res."},{"issue":"6","key":"689_CR54","doi-asserted-by":"crossref","first-page":"413","DOI":"10.2165\/00003088-200039060-00003","volume":"39","author":"JC Fleishaker","year":"2000","unstructured":"Fleishaker JC. Clinical pharmacokinetics of reboxetine, a selective norepinephrine reuptake inhibitor for the treatment of patients with depression. Clin Pharmacokinet. 2000;39(6):413\u201327.","journal-title":"Clin Pharmacokinet."},{"issue":"3","key":"689_CR55","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1093\/sleep\/24.3.282","volume":"24","author":"O Larrosa","year":"2001","unstructured":"Larrosa O, de la Llave Y, Bario S, Granizo JJ, Garcia-Borreguero D. Stimulant and anticataplectic effects of reboxetine in patients with narcolepsy: a pilot study. Sleep. 2001;24(3):282\u20135.","journal-title":"Sleep."},{"issue":"Supplement_1","key":"689_CR56","doi-asserted-by":"crossref","first-page":"A24","DOI":"10.1093\/sleep\/zsz067.057","volume":"42","author":"Cedric O'Gorman","year":"2019","unstructured":"O\u2019Gorman C, Jones A, Tabuteau H. Scientific rationale and clinical development of AXS-12 for narcolepsy [abstract no. 0058]. Sleep. 2019;42(suppl 1):A24\u20135.","journal-title":"Sleep"},{"issue":"6","key":"689_CR57","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1136\/jnnp.2008.161588","volume":"80","author":"Y Dauvilliers","year":"2009","unstructured":"Dauvilliers Y, Paquereau J, Bastuji H, Drouot X, Weil JS, Viot-Blanc V. Psychological health in central hypersomnias: the French Harmony study. J Neurol Neurosurg Psychiatry. 2009;80(6):636\u201341.","journal-title":"J Neurol Neurosurg Psychiatry."},{"issue":"1","key":"689_CR58","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1046\/j.1365-2869.2001.00234.x","volume":"10","author":"E Daniels","year":"2001","unstructured":"Daniels E, King MA, Smith IE, Shneerson JM. Health-related quality of life in narcolepsy. J Sleep Res. 2001;10(1):75\u201381.","journal-title":"J Sleep Res."},{"key":"689_CR59","unstructured":"Theranexus announces preliminary results of phase II trial of THN102 on narcolepsy patients [press release]. 2019. https:\/\/www.theranexus.com\/images\/pdf\/Theranexus_PR_result_narcolepsy_20199227_VDEF.pdf. Accessed 26 Apr 2019"},{"key":"689_CR60","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.neuropharm.2013.04.019","volume":"75","author":"X Liu","year":"2013","unstructured":"Liu X, Petit JM, Ezan P, Gyger J, Magistretti P, Giaume C. The psychostimulant modafinil enhances gap junctional communication in cortical astrocytes. Neuropharmacology. 2013;75:533\u20138.","journal-title":"Neuropharmacology."},{"key":"689_CR61","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.neuroscience.2015.12.007","volume":"323","author":"JM Petit","year":"2016","unstructured":"Petit JM, Magistretti PJ. Regulation of neuron-astrocyte metabolic coupling across the sleep-wake cycle. Neuroscience. 2016;323:135\u201356.","journal-title":"Neuroscience."},{"issue":"7","key":"689_CR62","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1093\/ijnp\/pyy027","volume":"21","author":"D Vodovar","year":"2018","unstructured":"Vodovar D, Duchene A, Wimberley C, Leroy C, Pottier G, Dauvilliers Y, et al. Cortico-amygdala-striatal activation by modafinil\/flecainide combination. Int J Neuropsychopharmacol. 2018;21(7):687\u201396.","journal-title":"Int J Neuropsychopharmacol."},{"issue":"6","key":"689_CR63","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.5665\/sleep.5854","volume":"39","author":"A Duchene","year":"2016","unstructured":"Duchene A, Perier M, Zhao Y, Liu X, Thomasson J, Chauveau F, et al. Impact of astroglial connexins on modafinil pharmacological properties. Sleep. 2016;39(6):1283\u201392.","journal-title":"Sleep."},{"key":"689_CR64","unstructured":"Safety and efficacy of THN102 on sleepiness in narcoleptic patients [ClinicalTrials.gov identifier NCT02821715]. National Institutes of Health, ClinicalTrials.gov. 2018.\u00a0https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02821715. Accessed 26 Apr 2019."},{"key":"689_CR65","unstructured":"Theranexus provides 2018 full-year results and update on activities [press release]. 2019. https:\/\/www.actusnews.com\/en\/THERANEXUS\/pr\/2019\/04\/17\/theranexus-provides-2018-full-year-results-and-update-on-activities. Accessed 02 May 2019."},{"issue":"Supplement_1","key":"689_CR66","doi-asserted-by":"crossref","first-page":"A57","DOI":"10.1093\/sleep\/zsz067.138","volume":"42","author":"Ramakrishna Nirogi","year":"2019","unstructured":"Nirogi R, Bhyrapuneni G, Abraham R, Subramanian R, Goyal VK, Pandey SK, et al. SUVN-G3031, a potent and selective histamine H3 receptor inverse agonist - phase-2 investigational new drug for the treatment of narcolepsy - differentiating factors with competitor clinical candidates [abstract no. 0139]. Sleep. 2019;42(suppl 1):A57.","journal-title":"Sleep"},{"issue":"Supplement_1","key":"689_CR67","doi-asserted-by":"crossref","first-page":"A22","DOI":"10.1093\/sleep\/zsz067.053","volume":"42","author":"Vijay Benade","year":"2019","unstructured":"Benade V, Daripelli S, Tirumalasetty C, Subramanian R, Petlu S, Badange R, et al. SUVN-G3031, a histamine H3 receptor inverse agonist produces wake promoting effect in orexin-2-saporin lesioned rats [abstract no. 0054]. Sleep. 2019;42(suppl 1):A22\u20133.","journal-title":"Sleep"},{"issue":"Supplement_1","key":"689_CR68","doi-asserted-by":"crossref","first-page":"A50","DOI":"10.1093\/sleep\/zsz067.119","volume":"42","author":"Gopinadh Bhayrapuneni","year":"2019","unstructured":"Bhayrapuneni G, Kamuju V, Gandipudi S, Jayarajan P, Abraham R, Bojja K, et al. SUVN-G3031, a novel, potent and selective histamine H3 receptor inverse agonist for the treatment of narcolepsy: preclinical characterization [abstract no. 0120]. Sleep. 2019;42(suppl 1):A50.","journal-title":"Sleep"},{"issue":"Supplement_1","key":"689_CR69","doi-asserted-by":"crossref","first-page":"A22","DOI":"10.1093\/sleep\/zsz067.052","volume":"42","author":"Ramakrishna Nirogi","year":"2019","unstructured":"Nirogi R, Shinde A, Mudigonda K, Bhyrapuneni G, Muddana NR, Palacharla RC, et al. SUVN-G3031: safety, tolerability and pharmacokinetics of a potent and selective histamine H3 receptor inverse agonist - single and multiple ascending doses in healthy subjects [abstract no. 0053]. Sleep. 2019;42(suppl 1):A22.","journal-title":"Sleep"},{"issue":"4","key":"689_CR70","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1080\/13543784.2018.1459561","volume":"27","author":"S Takenoshita","year":"2018","unstructured":"Takenoshita S, Sakai N, Chiba Y, Matsumura M, Yamaguchi M, Nishino S. An overview of hypocretin based therapy in narcolepsy. Expert Opin Investig Drugs. 2018;27(4):389\u2013406.","journal-title":"Expert Opin Investig Drugs."},{"key":"689_CR71","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1756286419875622","volume":"12","author":"L Barateau","year":"2019","unstructured":"Barateau L, Dauvilliers Y. Recent advances in treatment for narcolepsy. Ther Adv Neurol Disord. 2019;12:1\u201312.","journal-title":"Ther Adv Neurol Disord."},{"issue":"Supplement_1","key":"689_CR72","doi-asserted-by":"crossref","first-page":"A23","DOI":"10.1093\/sleep\/zsz067.054","volume":"42","author":"Haruhide Kimura","year":"2019","unstructured":"Kimura H, Ishikawa T, Yukitake H, Suzuki M. An orexin 2 receptor-selective agonist, TAK-925, ameliorates narcolepsy-like symptoms and obesity in orexin\/ataxin-3 transgenic mice [abstract no. 0055]. Sleep. 2019;42(suppl 1):A23.","journal-title":"Sleep"},{"issue":"suppl_1","key":"689_CR73","doi-asserted-by":"crossref","first-page":"A1","DOI":"10.1093\/sleep\/zsy061.000","volume":"41","author":"M Suzuki","year":"2018","unstructured":"Suzuki M, Yukitake H, Ishikawa T, Kimura H. An orexin 2 receptor-selective agonist TAK-925 ameliorates narcolepsy-like symptoms in orexin\/ataxin-3 mice [abstract no. 0001]. Sleep. 2018;41(suppl):A1.","journal-title":"Sleep"},{"key":"689_CR74","doi-asserted-by":"crossref","unstructured":"Evans R, Tanaka S, Tanaka S, Touno S, Shimizu K, Sakui S, et al. A phase 1 single ascending dose study of a novel orexin 2 receptor agonist, TAK-925, in healthy volunteers (HV) and subjects with narcolepsy type 1 (NT1) to assess safety, tolerability, pharmacokinetics, and pharmacodynamic outcomes [oral presentation]. World Sleep Congress; 20\u201325 Sep 2019; Vancouver.","DOI":"10.1016\/j.sleep.2019.11.290"},{"key":"689_CR75","doi-asserted-by":"crossref","unstructured":"Ishikawa T, Suzuki M, Kajita Y, Miyanohana Y, Koike T, Kimura H. Discovery of a novel, orally available orexin 2 receptor-selective agonist, TAK-994, as a therapeutic drug for narcolepsy [abstract]. Biennial World Sleep Congress; 20\u201325 Sep 2019; Vancouver.","DOI":"10.1016\/j.sleep.2019.11.468"},{"key":"689_CR76","doi-asserted-by":"crossref","unstructured":"Kimura H, Ishikawa T, Suzuki M. A novel, orally available orexin 2 receptor-selective agonist, TAK-994, ameliorates narcolepsy-like symptoms in narcolepsy mouse models [abstract]. Biennial World Sleep Congress; 20\u201325 Sep 2019; Vancouver.","DOI":"10.1016\/j.sleep.2019.11.554"},{"issue":"10","key":"689_CR77","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/s40263-017-0464-6","volume":"31","author":"L Barateau","year":"2017","unstructured":"Barateau L, Liblau R, Peyron C, Dauvilliers Y. Narcolepsy type 1 as an autoimmune disorder: evidence, and implications for pharmacological treatment. CNS Drugs. 2017;31(10):821\u201334.","journal-title":"CNS Drugs."},{"key":"689_CR78","unstructured":"Clinical outcomes in narcolepsy and cataplexy: an evaluation of reboxetine treatment (CONCERT) (CONCERT) [ClinicalTrials.gov identifier NCT03881852]. National Institutes of Health, ClinicalTrials.gov. 2019. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03881852. Accessed 29 Apr 2019."},{"key":"689_CR79","unstructured":"A study of the efficacy and safety of JZP-258 in subjects with narcolepsy with cataplexy [ClinicalTrials.gov identifier NCT03030599]. National Institutes of Health, ClinicalTrials.gov. 2018. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03030599. Accessed 29 Apr 2019."}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-019-00689-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40263-019-00689-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-019-00689-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T07:47:28Z","timestamp":1722325648000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40263-019-00689-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":79,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["689"],"URL":"https:\/\/doi.org\/10.1007\/s40263-019-00689-1","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"17 January 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This work and open access was funded by Jazz Pharmaceuticals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Michael J. Thorpy is a consultant and\/or a researcher for Jazz, Axsome, Balance, Avadel\/Flamel, Harmony and Suven.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}